The University of Arizona/Arizona Cancer Center (ACC) has been a continuously funded member institution of the Southwest Oncology Group (SWOG) since 1974. The current renewal application requests funding for years 37-41 to continue and expand institutional participation in the clincal research and treatment goals of SWOG via SWOG-and SWOG-endorsed efforts.
Specific aims and objectives remain as follows: 1. To continue to meet institutional scientific leadership and core service commitments within the Group, including: (a) protocol coordination (multiple studies);(b) disease and discipline committee administration;(c) reference and repository laboratory administration (including lymphoma, myeloma);(d) Group quality assurance and quality control. 2. To continue to promote the rapid integration of promising new research leads, including those developed at the ACC, into cooperative group testing to provide treatment options for a larger population of patients and improved patient care. 3. To continue to meet institutional clinical research commitments in the recruitment of appropriate patients for SWOG and SWOG-endorsed studies and all attendant commitments to longterm fllowup, quality assurance, quality control. 4. To continue and increase effforts to promote physician and patient awareness of and participation in SWOG and SWOG-endorsed clinical trials and outreach programs. 5. To continue efforts to understand factors affecting accrual paticularly those in special populations (eg, minority, elderly, financially disadvantaged) and to implement appropriate interventions where possible.
The ACC has a long history of scientific and administrative leadership in the SWOG and participation in national cooperative group treatment and prevention studies. A key element of its scientific contribution is institutional clinical and laboratory pilot work leading to national testing to establish new standards of care.
|Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493|
|Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153|
|Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571|
|Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527|
|Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19|
|Ravandi, Farhad; Othus, Megan; O'Brien, Susan M et al. (2016) US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv 1:250-259|
Showing the most recent 10 out of 211 publications